SYNERGY™
Everolimus-Eluting Platinum Chromium Coronary Stent System
The First DES Indicated for Use in High Bleeding Risk Patients*
The SYNERGY Bioabsorbable Polymer Stent was intentionally designed to enable short DAPT.
The SYNERGY BP Stent was the first FDA-approved drug-eluting stent with abluminal bioabsorbable polymer coating available in the U.S. It was designed to address the challenges associated with permanent polymer stents such as inflammation, neoatherosclerosis and late stent thrombosis.
The SYNERGY BP Stent provides synchronous drug elution and polymer absorption; the polymer is absorbed shortly after the drug elution is complete at 3-months, providing rapid healing and freedom from long-term polymer exposure. Learn more
In over 18,000 patients across 9 studies, the SYNERGY BP Stent shows outstanding safety with consistently low stent thrombosis rates1. View the clinical evidence
Ordering Information
Early Healing
Advanced design for optimal healing
Clinical Outcomes
Outstanding evidence across trials
Studying DAPT
Intentionally designed to enable short DAPT
